- Home
- PRPL vs ACHV Comparison
PRPL vs ACHV Comparison
Compare PRPL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- ACHV
- Stock Information
- Founded
- PRPL 2010
- ACHV N/A
- Country
- PRPL United States
- ACHV Canada
- Employees
- PRPL N/A
- ACHV N/A
- Industry
- PRPL Home Furnishings
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PRPL Consumer Discretionary
- ACHV Health Care
- Exchange
- PRPL Nasdaq
- ACHV Nasdaq
- Market Cap
- PRPL 96.8M
- ACHV 92.6M
- IPO Year
- PRPL N/A
- ACHV N/A
- Fundamental
- Price
- PRPL $0.77
- ACHV $2.70
- Analyst Decision
- PRPL Hold
- ACHV Strong Buy
- Analyst Count
- PRPL 2
- ACHV 4
- Target Price
- PRPL $1.25
- ACHV $15.75
- AVG Volume (30 Days)
- PRPL 1.4M
- ACHV 162.2K
- Earning Date
- PRPL 03-13-2025
- ACHV 03-11-2025
- Dividend Yield
- PRPL N/A
- ACHV N/A
- EPS Growth
- PRPL N/A
- ACHV N/A
- EPS
- PRPL N/A
- ACHV N/A
- Revenue
- PRPL $487,877,000.00
- ACHV N/A
- Revenue This Year
- PRPL $3.96
- ACHV N/A
- Revenue Next Year
- PRPL $8.16
- ACHV N/A
- P/E Ratio
- PRPL N/A
- ACHV N/A
- Revenue Growth
- PRPL N/A
- ACHV N/A
- 52 Week Low
- PRPL $0.65
- ACHV $2.51
- 52 Week High
- PRPL $2.12
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- PRPL 41.00
- ACHV 41.28
- Support Level
- PRPL $0.79
- ACHV $2.70
- Resistance Level
- PRPL $0.90
- ACHV $2.99
- Average True Range (ATR)
- PRPL 0.08
- ACHV 0.20
- MACD
- PRPL 0.00
- ACHV 0.01
- Stochastic Oscillator
- PRPL 26.60
- ACHV 34.55
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.